September 21, 2017
MYLAN LABORATORIES LIMITED, (Petitioner)
v.
AVENTIS PHARMA S.A. (Patent Owner)
Case IPR2016-00712
Patent 8,927,592 B2
The PTAB ordered that Sanofi’s (Aventis Pharma S.A.) patent claims to uses of Cabazitaxel have been proved to be unpatentable by a preponderance of the evidence.
Cabazitaxel
4α-acetoxy-2α-benzoyloxy-5β, 20-epoxy-lβ-hydroxy-7β, 10β-dimethoxy-9-oxo-ll-taxen-13α-yl(2R,3S)-3tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate.